Due to the rise of the biotechnology market and the golden period it is going through right now, investors are eager to buy large number of shares from different biotech companies on the healthcare market. But there is always a conundrum as to which stock would last long and which stock would be more begetting. There are a couple of obvious choices which are evident to any investor, choices that stand out, but there are a couple of companies that are like hidden gems or are small but still hold potential to give you large returns.
Amgen Inc. (NASDAQ:AMGN) is a biotech company and one of the most formidable on the market currently. The past two quarters turned out very lucrative for the company and cemented its position as the top blue chip biotech company on the market. In the fourth quarter the company rose from 186 million to 1.7 billion, which is a large profit. The company pays 2.05 percent dividends per share which is huge for a biotech company. So when we were talking about obvious choices, consider Amgen Inc. (NASDAQ:AMGN) one of those.
Biogen Idec Inc. (NASDAQ:BIIB) comes on the list of blue chip biotech stocks because the analysts claim that this year will turn out to be immensely profitable for the company. Wall Street hails the company as the most trustworthy stock on the biotech market. The inventory of the company is rich because Biogen Idec Inc. (NASDAQ:BIIB) has been working on introducing various antibodies for diseases that are usually regarded as hard to treat. Biogen Idec Inc. (NASDAQ:BIIB) is a buy worthy of investors’ attention and if you are an investor, you should certainly consider Biogen Idec Inc. (NASDAQ:BIIB).
Celgene Corp. (NASDAQ:CELG) is a well known name in the biotech market. With a healthy pipeline and numerous drugs lined up for 2016, the company is expected to grow by 20 percent in two years. With an expected profit like that, it’s an attractive stock for the investors. It’s also well known for its rich alliances with other healthcare companies, making its inventory a rich tapestry of powerful and efficient drugs that are on high demand in the market.
At the conclusion of this piece we mention Gilead Sciences Inc. (NASDAQ:GILD), which is the top cap holder when it comes to profits. Gilead Sciences Inc. (NASDAQ:GILD) is the stock that has been responsible for keeping the biotech market stable. It is also responsible for keeping the whole industry alive. The stock has waned since the beginning of this year due to various reasons but Gilead Sciences Inc. (NASDAQ:GILD) is still a strong buy. Even though it isn’t that formidable as it was months ago, it certainly is the godfather of the biotech market, which single handedly revived the market and made way for other companies to follow suit. Gilead Sciences Inc. (NASDAQ:GILD) is a buy worth every investor’s attention which can’t be neglected in any case.
